Non-infectious Dacryoadenitis.
Singh S, Selva D.
Surv Ophthalmol. 2022 Mar-Apr;67(2):353-368. doi: 10.1016/j.survophthal.2021.05.011. Epub 2021 May 31.
Infectious Dacryoadenitis: A Comprehensive Review.
Wai KM, Wolkow N, Yoon MK.
Int Ophthalmol Clin. 2022 Apr 1;62(2):71-86. doi: 10.1097/IIO.0000000000000412.
The many facets of dacryoadenitis.
Mombaerts I.
Curr Opin Ophthalmol. 2015 Jul;26(5):399-407. doi: 10.1097/ICU.0000000000000183.
SLE dacryoadenitis.
Hung YC, Wang DD, Han LSM, Betts TD, Weatherhead RG.
Orbit. 2019 Aug;38(4):338-341. doi: 10.1080/01676830.2018.1518463. Epub 2018 Dec 12.
Bilateral tuberculous dacryoadenitis.
Ayari R, Amri R, Chalbi E, Sbai MA.
Int J Mycobacteriol. 2020 Jul-Sep;9(3):332-334. doi: 10.4103/ijmy.ijmy_57_20.
The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis.
Kanda M, Nagahata K, Moriyama M, Takano KI, Kamekura R, Yoshifuji H, Tsuboi H, Yamamoto M, Umehara H, Umeda M, Sakamoto M, Maehara T, Inoue Y, Kubo S, Himi T, Origuchi T, Masaki Y, Mimori T, Dobashi H, Tanaka Y, Nakamura S, Takahashi H.
Mod Rheumatol. 2025 Apr 8;35(3):542-547. doi: 10.1093/mr/roae096.
Dacryoadenitis post COVID-19 infection and immunization.
Singh S, Gandhi A, Das S.
Indian J Ophthalmol. 2023 Aug;71(8):3100-3102. doi: 10.4103/IJO.IJO_30_23.
Mesenchymal stem cells for treating autoimmune dacryoadenitis.
Lu X, Wang X, Nian H, Yang D, Wei R.
Stem Cell Res Ther. 2017 Jun 5;8(1):126. doi: 10.1186/s13287-017-0593-3.
Dacryoadenitis in giant cell arteritis.
Meurisse PL, Eid L, Rousseau A.
J Fr Ophtalmol. 2022 Sep;45(7):829-830. doi: 10.1016/j.jfo.2021.11.020. Epub 2022 Jun 24.
Dacryoadenitis: do not forget ANCA vasculitis.
Derbel A, Salah RB, Boukhzar R, Frikha F, Marzouk S, Bahloul Z.
Rom J Ophthalmol. 2024 Apr-Jun;68(2):187-190. doi: 10.22336/rjo.2024.35.
